Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label, Multicenter Trial Of Femera (Letrozole) 2.5 mg As First-line Therapy In Postmenopausal Women With Metastatic Breast Cancer Relapsing Following Adjuvant Tamoxifen Therapy

NCT00014638 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00014638
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00014638 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label, Multicenter Trial Of Femera (Letrozole) 2.5 mg As First-line Therapy In Postmenopausal Women With Metastatic Breast Cancer Relapsing Following Adjuvant Tamoxifen Therapy
Lead sponsor
Novartis
Phase
Phase 4
Overall status
Completed
Start date
January 31, 2001
Completion date
March 31, 2002
Enrollment
Not reported
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer